News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Insmed Incorporated (INSM) Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release


10/19/2005 5:13:08 PM

RICHMOND, Va.--(BUSINESS WIRE)--Sept. 29, 2005--Insmed Incorporated (NASDAQ:INSM) today released the following statement: The company wishes to clarify a statement in the press release issued September 27, 2005 regarding iPlex (rhIGF-I/rhIGFBP-3) (Mecasermin rinfibate). With respect to the orphan exclusivity issue, Insmed wants to be clear that the FDA has not yet determined whether the recent approval and granting of orphan exclusivity for Mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will block the approval of iPlex. The Agency is still considering the issue.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES